KospicyKorean filings in English
Companies / BioNote

BioNote

(주)바이오노트

KOSPI · 377740KSIC 213FY ends month 12Consolidated statementsMarket view
Revenue (TTM)
129.0 bn
Revenue growth
12.1%
Operating margin
18.3%
Net margin
-162.0%
ROE
-13.2%

Quarterly results

KRW bn2024 Q42025 Q12025 Q22025 Q32025 Q42026 Q12026 Q22026 Q3
Revenue24.728.432.429.528.032.636.432.1
Operating income2.54.76.34.80.86.38.58.0
Net income11.14.084.517.9-194.041.39.1-65.3
Cash from operations21.81.03.35.64.510.525.08.0
Free cash flow17.4-2.40.84.93.09.823.9-9.1

Annual results

KRW bn202320242025
Revenue90.1102.8118.3
Operating income-47.012.216.7
Net income-20.555.3-87.5
Cash from operations-4.257.914.4
Free cash flow-8.247.56.3

Other ratios trailing 12 months

Gross margin56.7%
ROA-12.8%
Liabilities / equity0.03x
Current ratio36.51x
FCF margin21.4%
CFO / net income-0.23x

Recent filings

FilingForm
Thu 19 Nov 2026
Proxy Solicitation MaterialDEF 14ADART
Notice of Shareholders' MeetingDEF 14ADART
Fri 13 Nov 2026
Quarterly Report — 2026.0910-QDART
Thu 12 Nov 2026
Preliminary Consolidated Operating Results (Fair Disclosure)8-KEN form
Tue 10 Nov 2026
[Amendment] Board Resolution to Convene Shareholders' MeetingDEF 14A/AEN form
Mon 26 Oct 2026
Record Date / Shareholder Register Closure8-KDART
Board Resolution to Convene Shareholders' MeetingDEF 14ADART